1. Omalizumab alleviated itchiness and reduced hives in patients with chronic idiopathic urticaria refractory to H1-antihistamine therapy.
2. Serious adverse events are more common with higher doses, to the limited extent of safety evaluations in this study.
Based on a phase-3 clinical study published today, omalizumab shows promise for alleviating...